TimesSquare Capital Management LLC Has $37.02 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

TimesSquare Capital Management LLC lifted its stake in Repligen Co. (NASDAQ:RGEN) by 61.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 205,883 shares of the biotechnology company’s stock after purchasing an additional 78,591 shares during the period. TimesSquare Capital Management LLC’s holdings in Repligen were worth $37,018,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Artisan Partners Limited Partnership boosted its position in shares of Repligen by 11.3% during the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after buying an additional 157,807 shares during the period. Wellington Management Group LLP lifted its position in Repligen by 2.1% during the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after purchasing an additional 29,215 shares during the period. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 0.4% during the 4th quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after acquiring an additional 2,590 shares in the last quarter. Parnassus Investments LLC bought a new position in shares of Repligen in the 3rd quarter valued at $87,475,000. Finally, Northern Trust Corp grew its position in Repligen by 2.4% in the third quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company’s stock valued at $75,040,000 after acquiring an additional 11,204 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on RGEN. JPMorgan Chase & Co. dropped their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. KeyCorp boosted their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Stock Down 0.4 %

Shares of RGEN traded down $0.61 during mid-day trading on Thursday, reaching $164.89. The company had a trading volume of 419,610 shares, compared to its average volume of 536,302. The firm has a 50-day moving average price of $179.23 and a 200 day moving average price of $174.56. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The company has a market capitalization of $9.21 billion, a price-to-earnings ratio of 650.00, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 earnings per share. On average, sell-side analysts forecast that Repligen Co. will post 1.46 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,597 shares of company stock valued at $5,039,532. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.